Metagenomi Therapeutics (MGX) Non Operating Income (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Non Operating Income of $1.5 million for Q1 2026, down 46.58% year-over-year from $2.9 million in Q1 2025, and down 17.89% quarter-over-quarter from $1.9 million in Q4 2025.
Metagenomi Therapeutics (MGX) Non Operating Income (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Non Operating Income for 4 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income fell 46.58% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $6.7 million (up 55.98% YoY), while the FY2025 annual figure was $8.1 million, up 51.73% from the prior year.
- Non Operating Income eased to $1.5 million in Q1 2026 per MGX's latest filing, from $1.9 million in the prior quarter.
- Across five years, Non Operating Income topped out at $6.9 million in Q2 2023 and bottomed at -$4.0 million in Q4 2024.
- Historically, Non Operating Income has averaged $2.6 million across 4 years, with a median of $2.9 million in 2025.
- Annual changes were most pronounced in 2024 — Non Operating Income sank 209.79% — and 2025, when it soared 147.02%.
- Metagenomi Therapeutics' Non Operating Income stood at $3.6 million in 2023, then tumbled by 209.79% to -$4.0 million in 2024, then jumped by 147.02% to $1.9 million in 2025, then fell by 17.89% to $1.5 million in 2026.
- Business Quant data shows MGX's Non Operating Income at $1.5 million in Q1 2026, $1.9 million in Q4 2025, and $2.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | 1.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.29 Mn |
| Mar 31, 2026 | 1.54 Mn |
| Dec 31, 2025 | 1.87 Mn |
| Sep 30, 2025 | 2.21 Mn |
| Jun 30, 2025 | 1.12 Mn |
| Mar 31, 2025 | 2.88 Mn |
| Dec 31, 2024 | -3.98 Mn |
| Sep 30, 2024 | 1.50 Mn |
| Jun 30, 2024 | 3.93 Mn |
| Mar 31, 2024 | 3.88 Mn |
| Dec 31, 2023 | 3.63 Mn |
| Sep 30, 2023 | 3.78 Mn |
| Jun 30, 2023 | 6.85 Mn |
| Mar 31, 2023 | 4.00 Mn |